Earlier this month, Merck and Daiichi Sankyo announced that ifinatamab deruxtecan was granted Breakthrough Therapy Designation by the U.S. FDA for treating adult patients with extensive-stage small ...

Merck & Co (NYSE: MRK) and Daiichi Sankyo (TYO: 4568) have received Breakthrough Therapy designation from the US regulator ...

Merck MRK announced that the FDA has granted the Breakthrough Therapy designation (BTD) to its B7-H3-directed DXd ...

Rahway: Merck and Daiichi Sankyo have announced that Ifinatamab deruxtecan (I-DXd) has been granted Breakthrough Therapy ...

BASKING RIDGE, N.J. & RAHWAY, N.J., August 06, 2024--Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, have expanded their existing global ...

In a deal announced Thursday, Merck will pay Daiichi Sankyo $5.5 billion over the next two years for rights to co-develop and co-market the three medicines, which are in various stages of clinical ...

Merck & Co. will co-develop three of Daiichi Sankyo’s clinical-phase, DXd antibody-drug conjugate (ADC) candidates for various cancers, through a collaboration that could generate up to an eye ...

On Oct. 19, narrow-moat Daiichi Sankyo announced an out-licensing deal with Merck for three of Daiichi’s antibody-drug conjugate candidates. The total up-front payments are $5.5 billion, up to ...

AbbVie ABBV is known for its strong immunology franchise comprising blockbuster drugs like Skyrizi, Rinvoq and Humira.

Merck to pay Daiichi Sankyo a $4 billion upfront payment in addition to $1.5 billion in continuation payments over the next 24 months, and may make additional payments of up to $16.5 billion ...

(RTTNews) - Daiichi Sankyo Company Limited (DSKYF.PK) and Merck & Co Inc. (MRK) Tuesday said they have expanded their development and commercialization agreement to include Merck's MK-6070, an ...